Report questions use of arsenic compound for leukaemiaBMJ 2001; 323 doi: https://doi.org/10.1136/bmj.323.7307.252/d (Published 04 August 2001) Cite this as: BMJ 2001;323:252
- Scott Gottlieb
- New York
A new report has raised questions about the safety of arsenic trioxide, a compound recently approved in the United States for treating acute promyelocytic leukaemia, a rare subtype of acute myelogenous leukaemia.
In a study of 10 patients who had leukaemia that had relapsed or had not responded to conventional treatment and who were taking arsenic trioxide, three died suddenly, researchers reported (Blood 2001;98:266-71).
Even though the compound may provide benefits to some patients with leukaemia, “arsenic trioxide may be significantly, …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial